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Genomic Profiling of Thyroid Cancer
Reveals a Role for Thyroglobulin in Metastasis
Abdul K. Siraj,1 Tariq Masoodi,1,7 Rong Bu,1,7 Shaham Beg,1 Saif S. Al-Sobhi,2 Fouad Al-Dayel,3
Mohammed Al-Dawish,4 Fowzan S. Alkuraya,5,6,* and Khawla S. Al-Kuraya1,*
Papillary thyroid carcinoma (PTC) has a wide geographic variation in incidence; it is most common in Saudi Arabia, where it is only sec-
ond to breast cancer as the most common cancer among females. Genomic profiling of PTC from Saudi Arabia has not been attempted
previously. We performed whole-exome sequencing of 101 PTC samples and the corresponding genomic DNA to identify genes with
recurrent somaticmutations, then sequenced these genes by using a next-generation gene-panel approach in an additional 785 samples.
In addition to BRAF, N-RAS, and H-RAS, which have previously been shown to be recurrently mutated in PTC, our analysis highlights
additional genes, including thyroglobulin (TG), which harbored somatic mutations in 3% of the entire cohort. Surprisingly, although
TGmutations were not exclusive to mutations in the RAS-MAP kinase pathway, their presence was associated with a significantly worse
clinical outcome, which suggests a pathogenic role beyond driving initial oncogenesis. Analysis of metastatic PTC tissue revealed signif-
icant enrichment for TG mutations (p < 0.001), including events of apparent clonal expansion. Our results suggest a previously un-
known role of TG somatic mutations in the pathogenesis of PTC and its malignant evolution.Introduction
Thyroid cancer is the most common endocrine cancer, and
its incidence is increasing worldwide.1 Among females, it
is the secondmost commonmalignancy, after breast cancer,
in Saudi Arabia, where it accounts for 9% of all cancers and
12%of allmalignant cancers in females.2 Among the several
histological subtypes of thyroid cancer, papillary thyroid
carcinoma (PTC) is the most common subtype, comprising
approximately 80%–90% of all thyroid cancers.3 Although
PTC is usually a well-differentiated thyroid cancer with
favorable prognosis, the clinical behavior of PTC varies
widely.4,5 Approximately 20% of PTCs demonstrate tumor
recurrence, and some reach advanced stages.6 Various clini-
copathological variables, such as tall-cell variant, advanced
stage, vascular invasion, and nodal or distant metastasis,
are related to aggressive behavior of PTC.7,8 However, the
factors and mechanisms determining the aggressive
behavior of some papillary carcinomas that result in recur-
rence andmetastatic lesions are not fully known. Although
predisposition to PTC is known to occur secondary to germ-
line mutations in a few genes, including PTEN9,10(MIM:
601728), APC11(MIM: 611731), SEC23B12(MIM: 610512),
and HABP213(MIM: 603924), the overwhelming majority
of PTC cases are sporadic in nature.14 Available data from
genomic analysis of PTC suggest that it is a generally ‘‘quiet’’
cancer in terms of overall mutation burden, a feature that
facilitated the identification of driver mutations from the
relatively low background of passenger mutations.15 These
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encodingvarious componentsof themitogen-activatedpro-
tein kinase (MAPK) signaling pathway. Such genes include
BRAF (MIM: 164757); RAS (HRAS [MIM: 190020]; NRAS
[MIM: 164790] and KRAS [MIM: 190070]), RET (MIM:
164761), andNTRK116–19(MIM:191315). Recurrent somatic
mutations that are likely to drive oncogenesis in PTC have
also been identified in EIF1AX (MIM: 300186), PPM1D
(MIM: 605100), and CHEK215(MIM: 604373). Targeted
sequencing of candidate genes has also demonstrated the
prominent role of drivermutations inBRAF (59%), followed
by PIK3CA (12%) (MIM: 171834), TP53 (8%) (MIM:
191170), and NRAS (4%).20
Despite the recent advances in our understanding of the
genomic architecture of PTC, important issues remain to
be addressed. For example, the study by the Cancer
Genome Atlas Research Network did not target popula-
tions such as Italy,21 Japan,22 Denmark,23 and Saudi
Arabia,2 which are all known to have a high incidence of
PTC. This is likely to be relevant because the mutation pro-
file of cancer can vary greatly between different popula-
tions.24,25 Specific examples include the demonstration
of a higher incidence of PIK3CA amplifications (53.1%)
in Saudi thyroid cancer,26 higher incidence of amplifica-
tion of ESR1 (20.6%) (MIM: 133430), HER2 (31%) (MIM:
164870), and MYC (16%)(MIM: 190080) in Saudi breast
cancer,27,28 higher rate of EGFR (MIM: 131550) amplifica-
tions (15.3%) in Saudi lung cancers,29 lower incidence of
BRAF mutations (2.5%) in Saudi colorectal cancer,30 and
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higher incidence of PIK3CA amplification (40%) in Saudi
ovarian cancer.31
Therefore, genomic profiling of PTC in a country, such as
Saudi Arabia, where the disease is especially prevalent is
likely to provide new insights. Furthermore, previously
published genomic profiling specifically excluded PTC in-
dividuals with aggressive disease.15 Although this might
have ensured increased homogeneity of the study samples
as intended by those authors, it might have also limited
the authors’ ability to identify factors whose pathogenic
role concerns the advanced stages of malignancy, e.g.,
metastasis. In an attempt to address these gaps, we present
the results of our genomic profiling of >880 PTC samples
from Saudi individuals who span the full clinicopatholog-
ical spectrum. In addition to replicating previously identi-
fied genes with recurrent somatic mutations, we identify
and validate a few candidates. In particular, we highlight
a previously unrecognized role for somatic mutations of
the thyroglobulin gene (TG [MIM: 188450]) as a marker
of poor prognosis and a potential driver of metastasis.Materials and Methods
Clinical Samples
A total of 909 individuals diagnosed and treated between 1988 and
2015 at King Faisal Specialist Hospital and Research Centre and
Prince Sultan Military Medical City, Riyadh, Saudi Arabia were
selected. Fresh tumor samples were collected from the operation
room (OR) and were subjected to immediate frozen-section exami-
nation in the department of pathology. Tumor samples were
included in the study if examination both of frozen sections and
of formalin-fixed paraffin embedded (FFPE) sections confirmed
PTC. None of the individuals from whom fresh cancer tissues
were collected received any preoperative treatment in the form of
chemotherapy or radiotherapy. Along with fresh cancer tissue,
fresh blood in the EDTA tubewas also collected forDNAextraction.
FFPE blocks were also retrieved from the pathology department,
and tumor punches were made available for DNA extraction from
the tumor tissue area. Pathological and clinical data were retrieved
frommedical charts and the integrated clinical information system
(ICIS). Clinical risk assessment is given in the supplemental note.
All tissue and blood samples were obtained from individuals under
approval from the institutional review board of the hospital, and
informed consent was obtained from individuals for the study.
Clinicopathological Evaluation of Tumors
Tumor sections from all cases were subjected to histopathological
examination andwere only included in the study if the tumor area
showed an average of 60% of tumor cell nuclei and less than 20%
necrosis. The clinical and demographic elements included the
following: age at diagnosis, gender, histopathological subtype,
regional lymph node status (N), distantmetastasis (M), and overall
pathologic AJCC stage. The follow-up data elements included the
following: vital status (alive/dead), disease status (remission,
persistence, or progression), days to last contact or death, and
additional radiation therapy given. The median age at diagnosis
in the PTC cohort was 37 years, and 64.2% of individuals were
younger than 45 years of age. There 24.2% were male, and
75.8% were female; there was a male: female ratio of 1:3. The stag-The Americing of the submitted tumors was distributed across all four stages:
66.4% were stage I, 4.7% were stage II, 8.6% were stage III, 16.7%
were stage IV, and 3.6% of cases had an unknown overall stage.
72.4% were of classical papillary histological subtype, 14.8%
were follicular variants, and 7.8% were tall-cell variants. 1.2%
were rare types, and 3.8% were without histological annotation.
5.3% of individuals had distant metastatic disease.
Next-Generation Sequencing
We performed whole-exome and capture sequencing on an Illu-
mina HiSeq 2500 DNA Sequencer by using the Nextera Rapid
Capture Exome Kit and SureSelect Target Enrichment Kit, respec-
tively, according to the manufacture’s instruction.
Clinical Data Analysis
We used the JMP 10.0 (SAS Institute) software package for clinico-
pathological data analyses. We generated survival curves by using
the Kaplan-Meier method and evaluated significance with the
Mantel-Cox log-rank test. We calculated risk ratio by using the
Cox proportional hazard model. Values of p < 0.05 were consid-
ered statistically significant.
DNA Isolation
DNA from peripheral blood and from freshly frozen and paraffin-
embedded tissues was isolated with the Gentra DNA Isolation Kit
according to the manufacturer’s recommendations.
PCR and Sanger Sequencing
We used Primer 3 software to design the primers for the particular
variants identified by whole-exome or capture sequencing and all
coding exons and flanking intronic sequences of TG (these are
available upon request). PCR was performed in a total volume of
25 ml with 20 ng of genomic DNA, 2.5 ml 10 3 Taq buffer,
2.3 mM MgCl2, 0.2 mM dNTPs, 1 unit Taq polymerase, and
0.2 mM each primer and water. We confirmed the efficiency and
quality of the amplified PCR products by running them on a 2%
agarose gel. The PCR products were subsequently subjected to
Sanger sequencing with BigDye terminator V 3.1 cycle sequencing
reagents and analyzed on an ABI 3730XL DNA analyzer
(Applied Biosystems). Reference sequences were downloaded
from GenBank. Sequencing traces were analyzed with the Muta-
tion Surveyor v4.04 (Soft Genetics).
Next-Generation Gene-Panel Sequencing
808 DNA samples were analyzed for target-capture sequencing of
24 genes with the SureSelect Target Enrichment Kit on an Illumina
HiSeq 2500 Sequencer. The average coverage of the targeted region
was 6003, and 95% of the target was covered at>503. Sequencing
reads were aligned to the human genome (NCBI build 37) with the
BWA algorithm on default settings. Finally, 785 cases passed inter-
nal quality control and quality matrix and were included in
further analyses.
Bioinformatic Analysis
BCL files generated by Illumina for the whole-exome sequencing
samples were converted to FASTQ format by CASAVA software
(v.1.8.1, Illumina) and aligned to the human reference genome
hg19 with the Burrows-Wheeler Aligner32. Local realignment,
PCR duplicate marking, base-quality recalibration, and calculation
of coverage metrics were performed with GATK33 and Picard tools
(v.1.119, http://broadinstitute.github.io/picard/). Putative SNVsan Journal of Human Genetics 98, 1170–1180, June 2, 2016 1171
Figure 1. Correlation of Somatic Mutation Density with Clinical Parameters
(A) Somatic mutation density (in MB) in the 101 PTC exome cohort. The maximummutation density is 1.2 MB, and the median is 0.21
nonsynonymous somatic mutations per MB. Synonymous mutation density is compared with non-synonymous mutation density.
(B) Correlation of non-synonymous mutation density with MACIS score for mortality risk, which is significant (p ¼ 0.001).
(C) Correlation of non-synonymous mutation density with risk of recurrence (p ¼ 0.38).
(D) Correlation of non-synonymous mutations with individual’s age (p ¼ 0.008).
One outlier case was excluded for figure presentation in (B), (C) and (D). P values were estimated by Student’s t test.were called withMuTect,34 and putative somatic indels were called
with VarScan2 (http://varscan.sourceforge.net); tumor-normal
bam files were used as input. The identified variants were anno-
tated with ANNOVAR.35 We only considered variants that passed
the standard Mutect and VarScan2 filters, and we excluded com-
mon SNPs with minor allele frequency of > 0.001 as recorded in
dbSNP, the NHLBI exome sequencing project, 1000 Genomes,
and our in-house data from exome sequencing of around 700
normal samples. We also excluded variants in non-coding regions,
synonymous variants, and variants present in highly repetitive
regions. In addition, manually checking the mutations with the
Integrated Genomics Viewer filtered out the false positives. Similar
filters were also applied to the cohort of 785 capture sequencing
samples.Results
PTC Is a Relatively Quiet Tumor
Compared to other cancers, the thyroid cancer genome has
been shown to be relatively quiet and to involve fewer1172 The American Journal of Human Genetics 98, 1170–1180, Junegenetic mutations, which might explain why the disease
is often slow growing.15 PTC in our cohort of 101 cases
showed on average 0.82 nonsynonymous somatic muta-
tions per Mb. Surprisingly, one of the 101 samples ac-
counted for nearly 83% of all somatic mutations (16,821,
compared to a total of 20,118 from all samples combined).
When this sample was excluded, the average somatic mu-
tation rate dropped to 0.23 nonsynonymous somatic mu-
tations per Mb, which is comparable to what was reported
by the Cancer Genome Atlas Research Network (0.41) and
comparatively lower than the rate found in other cancers
(bladder ¼ 7.1, breast ¼ 1.2, colorectal ¼ 3.1, head and
neck ¼ 3.9, and ovarian ¼ 1.7)36 (Figure 1A). The mini-
mum density in our cohort was 0.00/MB, the maximum
was 1.21/MB, and the median was 0.21/MB). Mutation
density was associated with age (p ¼ 0.008) and mortality
risk (as measured by MACIS score; p ¼ 0.001) but not risk
of recurrence (ATA guideline 2009) (p ¼ 0.38) (Figures
1B–1D).2, 2016
Mutations in MAPK-Signaling-Pathway Genes Play a
Major Role in PTC Pathogenesis
The role of the MAPK pathway in tumorigenesis of differ-
entiated thyroid cancer is well known, and this pathway
is dysregulated in most cases of thyroid cancer.37 This
pathway is mainly activated in thyroid cancer by muta-
tions of BRAF and RAS (HRAS, NRAS, and KRAS) or rear-
rangements of RET-PTC, PAX8 (MIM: 167415), and/or
PPARg (MIM: 601487).38 In more than 95% of cases, the
activating point mutation of BRAF occurs at c.1799T>A,
resulting in p.Val600Glu (GenBank: NM_004333,
NP_004324) substitution.38 Recent data have also sug-
gested that mutations in BRAF are associated with a more
aggressive phenotype.39 RAS genes (HRAS, KRAS, and
NRAS) encode G proteins that signal to both the MAPK
and PI3K/AKT pathways. Point mutations in the RAS genes
typically occur in codons 12, 13, and 61 and are found in
40%–50% of follicular carcinomas and in 10%–20% of
PTCs.40–42
In our cohort, the MAPK-pathway gene mutations are
seen at a relatively high frequency of 66.6% (590/886)
(Table 1). This was primarily driven by BRAF mutation,
the frequency of which was 59.5% (521/875). BRAFmuta-
tion demonstrated strong association with adverse clinical
parameters such as old age (p< 0.001), tall-cell variant (p<
0.001), extra-thyroidal extension (p < 0.001), positive sur-
gical margin (p < 0.001), lymph-node metastasis (p <
0.001), and stage IV disease (p < 0.001). The second most
frequently mutated class of genes was RAS genes (Table 1).
NRAS was mutated in 5.4% of all cases (48/876) and
showed strong association with follicular variants of PTC
(p < 0.001). Mutual exclusivity was observed between
NRAS mutations and both lymph-node metastasis (p <
0.001) and extra-thyroidal extension (p ¼ 0.001). HRAS
mutations were seen at a frequency of 2.7% (24/886) and
showed an inverse association with lymph-node metas-
tasis (p ¼ 0.02), extra-thyroidal extension (p ¼ 0.02), and
surgical-margin positivity (p ¼ 0.02). Both HRAS and
NRAS were mutually exclusive with BRAF mutations (p <
0.001).
Identification of Candidate Genes in PTC
Pathogenesis
We analyzed WES from PTC and matched normal tissue to
search for genes with at least two somatic mutations in our
cohort of 101 samples. In addition to the MAPK-signaling-
pathway genes mentioned above (BRAF, NRAS, and HRAS),
we identified 21 genes (Table 1) that are recurrently
mutated in PTC tissues. In order to investigate a potential
role of these genes in the pathogenesis of PTC, we set
out to validate them in a replication cohort of 808 PTC in-
dividuals by capturing their exons and flanking intronic
sequences and then performing next-generation
sequencing. DNA quality was suboptimal for capture
sequencing in 23 samples, so we excluded these and pro-
ceeded with the analysis of 785 samples. 15 out of the 21
genes had at least one additional somatic mutation inThe Americthe replication cohort (Table 1 and Figure S1). By
combining the two cohorts, we identified recurrent muta-
tions in TG (3.05%), TP53 (0.9%),DNMT3A (1.47%) (MIM:
602769), and several candidate genes, including PKHD1
(1.14%) (MIM: 606702), SPTBN5 (1.14%) (MIM: 605916),
DNAH1 (0.79%) (MIM: 603332), CABIN1 (0.68%) (MIM:
604251), and MACC1 (0.56%) (MIM: 612646) (Table 1
and Figure 2).
TG Somatic Mutations Predict Poor Outcome and
Might Drive Metastatic Potential
We were particularly intrigued by the finding that TG is
recurrently mutated in PTC because of reports of thyroid
cancer in individuals with germline mutations in TG
with associated congenital hypothyroidism.43,44 First, we
set out to investigate the clinical relevance of TG somatic
mutations. In our cohort, 27 mutant cases were identified;
20 (74.1%) carried frameshift or splicing site mutations.
Seven (15.9%) cases harbored missense mutations. The
sequencing traces of three representative mutations,
c.2241dupT; p.Asn748*, c.1548_1550delAGA; p.Glu516del,
and c.4529þ1_2del (NM_003235) are presented in
Figure S2. Although only 3.05% of the entire cohort
harbored somatic mutations in TG (Table 1 and
Figure S3), these individuals had a significantly poorer clin-
ical outcome (p < 0.001) (Table S1) and were significantly
associated with aggressive clinical parameters such as old
age (p ¼ 0.01), recurrence (p ¼ 0.007), metastasis (p <
0.001), and stage IV (p ¼ 0.006) (Table S2). We then asked
whether this association was independently driven by TG
mutations rather than coexisting driver mutations because
77.7% (21/27) of TG mutation-positive PTC samples had
co-existing mutations in MAPK-pathway genes. Specif-
ically, we compared the clinical outcome of individuals
with coexisting mutations in TG and MAPK-pathway
genes to those with mutations in MAPK-pathway genes
only and found the former to be associated with signifi-
cantly poorer outcome (p < 0.001) (Figure 3). The observa-
tion that TGmutations are mostly observed in the context
of mutations in MAPK-pathway genes and that their pres-
ence significantly worsens the clinical outcome raises the
intriguing possibility that TG mutations might not drive
the initial oncogenesis of PTC but instead contribute
significantly to its malignant evolution. In particular,
distant metastasis, an already rare occurrence in PTC, was
significantly more common in TG-mutation-positive indi-
viduals than in those who lacked these mutations (p <
0.001). In order to test this hypothesis, we selectively
analyzed an independent cohort of 71 PTC-affected indi-
viduals with documented distant metastasis and found
that the frequency of somatic TG mutations increases by
more than 4-fold in these individuals as compared to the
original unselected cohort (12.7% versus 3.05%, p <
0.001). Based on these results that suggest a link between
TG mutations and distant metastasis, we set out to fully
sequence TG in distant metastases (brain, kidney, and
bone) from 11 PTC-affected individuals for whom distantan Journal of Human Genetics 98, 1170–1180, June 2, 2016 1173
Table 1. Recurrent Somatic Mutations from Exome and Gene Panel Sequencing
Serial
Number Gene
Exome 101 Cohort Gene Panel 785 Cohort Exome and Gene Panel
Number
of Mutations
Number
of Samples Total Frequency
Number
of Mutations
Number
of Samples Total Frequency
Number
of Mutations
Number
of Samples Total Frequency
1 BRAF 60 60 101 59.41 464 461 774 59.56 524 521 875 59.54
2 NRAS 1 1 101 0.99 47 47 775 6.06 48 48 876 5.48
3 TG 2 2 101 1.98 27 25 785 3.18 29 27 886 3.05
4 HRAS 2 2 101 1.98 22 22 785 2.8 24 24 886 2.71
5 DNMT3A 4 4 101 3.96 9 9 785 1.15 13 13 886 1.47
6 PKHD1 3 3 101 2.97 7 7 780 0.9 10 10 881 1.14
7 SPTBN5 2 1 101 0.99 10 9 781 1.15 12 10 882 1.13
8 TP53 2 2 101 1.98 6 6 785 0.76 8 8 886 0.9
9 DNAH1 2 2 101 1.98 5 5 782 0.64 7 7 883 0.79
10 CABIN1 2 2 101 1.98 4 4 781 0.51 6 6 882 0.68
11 MACC1 2 1 101 0.99 5 4 785 0.51 7 5 886 0.56
12 GPR98a 2 2 101 1.98 3 3 785 0.38 5 5 886 0.56
13 SNED1 2 2 101 1.98 2 2 780 0.26 4 4 881 0.45
14 TRIOBP 2 1 101 0.99 3 3 781 0.38 5 4 882 0.45
15 LTBP2 3 1 101 0.99 5 3 782 0.38 8 4 883 0.45
16 CAMKK2 2 2 101 1.98 2 2 785 0.25 4 4 886 0.45
17 ATP8B2 2 1 101 0.99 2 2 785 0.25 4 3 886 0.34
18 MLXIPL 2 2 101 1.98 0 0 783 0 2 2 884 0.23
19 GLRA3 2 1 101 0.99 1 1 784 0.13 3 2 885 0.23
20 NEFH 2 2 101 1.98 0 0 784 0 2 2 885 0.23
21 ZNF677 2 1 101 0.99 0 0 783 0 2 1 884 0.11
22 DENND4B 2 1 101 0.99 0 0 784 0 2 1 885 0.11
23 CRTAMb 2 1 101 0.99 0 0 785 0 2 1 886 0.11
24 SMU1 2 1 101 0.99 0 0 785 0 2 1 886 0.11
aNot validated by Sanger sequencing.
bTwo hits in the same codon in exome data.
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Figure 2. Frequency and Types of Muta-
tion in 24 Genes Detected by Exome
Sequencing
Different types of mutations are colored
differently. The majority of mutations are
missense (blue); there are two stop-gains
(red), three in-frame deletions (yellow
color), and one frame-shift mutation
(brown). The genes with a frequency of
1% share two somatic mutations except
that CRTAM shows two single nucleotide
changes within the same codon.metastatic tissue samples were available to us. Strikingly,
the frequency of TG somatic mutations was much higher
in this subgroup (36%) than in the overall cohort
(3.05%) (p < 0.001) (Figure 4). Importantly, our analysis
of the four metastatic samples with TG somatic mutations
revealed prominent heterozygous peaks, indicating that
most of the cells in the distant metastasis harbored these
mutations (Figure 5). This is particularly important in
that the corresponding primary PTC tissue was negative
for these TGmutations in three cases (Figure 4A). In order
to further investigate the possibility that metastatic tissues
are clonal expansions of cells with TG mutation, we care-
fully analyzed the next-generation-sequencing reads of
the corresponding TG segment in the corresponding pri-
mary PTC in those three cases and were able to detect
the TG mutation at an extremely low frequency in one
case (Figure S4).Discussion
Cancer genomics is one of the most promising app-
lications of personalized medicine: the traditional cate-
gorization of cancers based on their histopathological
appearance is replaced by genomic profiling aimed at
identifying the unique molecular signature that character-
izes each tumor and ultimately devising personalized
targeted therapy. Most previous studies of PTC genetics
suffer from the inherent bias of the search for somatic mu-
tations in pre-selected genes. As shown by The CancerThe American Journal of Human GeGenome Atlas study, a hypothesis-
free genomics approach is needed
for the identification of candidate
driver mutations in order to better
inform the design of targeted thera-
peutics.15
Using a similar genomics approach
on a relatively large collection of PTC-
affected individuals from a country
with one of the world’s highest inci-
dence of the disease allowed us to
unravel important molecular charac-
teristics. Consistent with our previous
experience with gene-level analysis ofPTC in Saudi Arabia, we showed that the MAPK signaling
pathway is an important player in the pathogenesis of
PTC and that somatic mutations in its various components
probably drive the oncogenic process. We have shown pre-
viously the synergistic effect of PIK3CA alteration on
the MAPK pathway in tumorigenesis of PTC and the possi-
bility of targeting this pathway for effective anticancer
therapy26. The role of the MAPK pathway in thyroid carci-
nogenesis has previously been reported in aggressive histo-
logical subtypes such as anaplastic thyroid cancer. Liu
et al.45 have shown that up to 95.8% of anaplastic thyroid
carcinomas harbor at least one genetic alteration in genes
of the receptor tyrosine kinase (RTK), PI3K/AKT, and
MAPK pathways. The same group earlier showed that
PTC develops de novo after oncogenic alteration of
MAPK pathway genes and, moreover, that its progression
to aggressive anaplastic thyroid carcinoma variant is facil-
itated by activation of the PI3K/AKT pathway.46
In addition to the recurrently mutated MAPK pathway
genes in our PTC cohort, TG was found to be recurrently
mutated (3.05%), as were TP53 (0.9%), DNMT3A
(1.47%), and a number of candidates, including PKHD1
(1.14%), CABIN1 (0.68%), and MACC1 (0.56%). TP53 is
one of the most frequently mutated genes in human can-
cers,47 and a role for TP53mutations in aggressive transfor-
mation of thyroid cancer has been proposed.48 A high
TP53 mutation rate of 3.5% (2/57) has been reported in
PTC on the basis of targeted next-generation sequencing
of a small cohort.20 The lower frequency observed in our
study (0.9%), which is similar that observed in the Cancernetics 98, 1170–1180, June 2, 2016 1175
Figure 3. Survival Analysis of Individuals Cohort
Kaplan Meier survival plot showing statistically significant poor survival of (A) TG-mutated cases compared to TG wild-type cases in the
overall cohort (p ¼ 0.0005) and (B) significant poor survival of TG-mutated cases in the MAPK-positive cohort as compared to
MAPK-positive individuals without TG mutation (p < 0.0001).Genome Atlas Research Network study (0.7%), is probably
more representative in light of the larger sample size. No
significant difference was observed between the recurrent
genes in our cohort and the TCGA gene list except for
NRAS, which was less frequently mutated in our cohort,
as shown in Table S3.
The role of DNMT3A is well documented and studied in
hematological malignancies such as acute myeloid leuke-
mia (AML [MIM: 601626]) andmyelodysplastic syndromes
(MDS [MIM: 614286]).49,50 Somatic mutation of DNMT3A
is predicted to have a poor outcome in individuals with
MDS.51 Mutations in this gene have also been reported
in other solid tumors, such as lung, breast, prostate, colo-
rectal, and gastric carcinomas.52 In our cohort, somatic
DNMT3A mutations were significantly associated with
adverse clinicopatholgical parameters such as old age
(p ¼ 0.002), extra-thyroidal extension (p ¼ 0.002), and
late-stage tumors (p ¼ 0.001). Although germline muta-
tions in PKHD1 cause autosomal-recessive polycystic kid-
ney disease (ARPKD [MIM: 263200]), it is considered one
of the candidate cancer genes for colorectal cancer,53 and
a role in pancreatic ductal adenocarcinoma has been docu-
mented.54 PKHD1mutations in our PTC cohort were corre-
lated with adverse clinicopatholgical parameters such as
old age (p ¼ 0.001) and late-stage tumors (p ¼ 0.009). Cal-
cineurin-binding protein 1 (CABIN1) has been shown to be
a negative regulator of TP53.55 This gene was mutated in
0.7% (6/881) of our PTC cohort and was significantly asso-
ciated with adverse clinicopatholgical parameters such as
old age (p ¼ 0.01) and late-stage tumors (p ¼ 0.003).
CABIN1 has been identified by gene-expression profiling
as a discriminating gene that predicts tumor recurrence
in stage III colorectal cancers.56 It is also one of the
cisplatin-resistance genes (CRA) responsible for chemore-
sistance to cisplatin therapy and is a potential candidate
for targeted therapies for counteracting cancer chemo-
therapy resistance.57 The gene encoding Metastasis Associ-
ated Colon Cancer 1 (MACC1) was mutated in 0.7%
(5/885) of our PTC cohort. MACC1 is a candidate gene1176 The American Journal of Human Genetics 98, 1170–1180, Junethat was first discovered in 2009 as a prognostic marker
and predictor of metastasis in colorectal cancer.58 It was
later shown that this gene plays a significant role in a num-
ber of other cancers, such as ovarian, liver, pancreatic,
lung, breast, and gastric cancers; esophageal osteosarcoma;
and glioma.59–67 This gene is not known to play a role in
thyroid cancer at this time.
One particularly intriguing finding of ours pertains to
TG. Several reports have highlighted the oncogenic poten-
tial of congenital hypothyroidism-associated germline TG
mutations.44 In this study, we found that somatic muta-
tions in TG, although uncommon (3.05%), appear to exert
significant effect on the evolution of PTC. The observation
that most TG mutation-positive PTC samples also
harbored mutations in genes encoding components of
the MAPK signaling pathway suggests that TG mutations
are not driver mutations per se. However, we show that
these TG mutations were nonetheless associated with a
significantly worse clinical outcome than were driver mu-
tations in the absence of TG mutations. This is consistent
with a role of TG mutations in driving the evolution of
PTC to a more aggressive phenotype. Consistent with
this notion is our finding that TG mutations appear to be
enriched in metastatic PTC compared to the localized
PTC. Metastasis in PTC is a very rare event, as can be
observed from our own cohort, where only 47 (5.3%) of
the 909 were diagnosed with distant metastasis. The
molecular underpinning of distant metastasis is poorly un-
derstood in cancers in general but is presumed to involve
additional mutational events that endow a subpopulation
of the primary cancer cells with new properties that allow
them to detach, migrate, invade, and seed in distant loca-
tions.68 Our finding that TG-mutation-positive metastasis
appear to have the TG mutation in the entire population
of tumor cells, whereas the corresponding primary tissue
can be negative for the same mutation is highly suggestive
that the TGmutation is one such event that endows a few
cells with the metastasis-conducive new properties.
Further support for this notion can be gleaned from the2, 2016
Figure 4. Increasing Proportion of TG-Mutated Cases in a Different PTC Cohort
(A) TG mutation in overall PTC cohort (3%).
(B) TG mutation in an independent metastatic PTC cohort (12.7%).
(C) TG mutation in available metastatic tissues (36.4%).one individual in whom a somatic mutation in TG was
present at an extremely low level in the primary tumor
but was nearly homogeneous in the distant metastasis.
These results suggest a model wherein TG somatic muta-
tions are rare events in PTC but when present greatly
enhance the metastasis potential of the tumor. If
confirmed by future studies, this model will have impor-
tant and clinically relevant consequences, not the least of
which is the potential of deep sequencing of TG to detect
low-level mosaicism in PTC as an independent prognostic
indicator of the cancer’s aggressiveness, including metas-
tasis potential.
In conclusion, we show that genomic profiling of PTC in
Saudi Arabia confirms the previously reported role ofmuta-
tions in MAPK pathway genes as likely drivers in the ma-
jority of cases. A few additional candidate genes were also
identified; elucidation of the role of these genes in PTC
pathogenesis awaits replication by future studies. Finally,
we show that TG mutations are strongly correlated with
poor clinical outcome, and although they do not appear
to drive initial oncogenesis, they are likely to drive the
aggressive evolution of PTC, including metastatic poten-Figure 5. TG Mutations Identified in Metastatic Tissue Samples
Sequencing traces of four TG mutations identified in metastatic tissu
c.454C>T (D), were not detected in corresponding PTC primary tum
traces of mutations identified in metastatic tissue samples, and top p
The Americtial. To the best of our knowledge, this is the first report
of a likely driver of metastasis in PTC.Accession Numbers
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